Deal Details

eMolecules Receives Investment From Avista

Healthcare
Industrial

eMolecules, investment from Avista

Summary

eMolecules, Inc. (“eMolecules” or the “Company”) received an investment from Avista Capital Partners (“Avista”). Terms of the transaction were not disclosed.

Baird served as the exclusive financial advisor to eMolecules, Inc. on this transaction.

About

eMolecules is driven to improve the human condition by enabling scientists to accelerate their research to find effective therapeutics. To achieve this, eMolecules provides business intelligence data and integrated ecommerce software for screening compound, chemical building blocks and primary antibody supply chains. These tools, combined with their acquisition, aggregation and analytical services, greatly empower drug discovery researchers working in the pharmaceutical, biotechnology, academia, CRO and agrochemical industries. A privately owned company, eMolecules was founded in 2005. The Company is headquartered in San Diego, California and has offices in Boston, Massachusetts and London, the United Kingdom, employing over 50 people across the three sites.

Avista Capital is a leading private equity firm with over $6 billion invested in more than 35 growth-oriented healthcare businesses globally. Avista partners with businesses that feature strong management teams, stable cash flows and robust growth prospects – investing in the medical devices and technologies, pharmaceuticals, outsourced pharmaceutical services, healthcare technology, healthcare distribution and consumer-driven healthcare sectors. Avista's Operating Executives and Advisors are an integral part of the team, providing strategic insight, operational oversight and senior counsel, which helps drive growth and performance, while fostering sustainable businesses and creating long-term value for all stakeholders. Avista is headquartered in New York, New York.

Healthcare
Industrial

eMolecules, investment from Avista